Creotech Instruments SA (CRI1)

Currency in PLN
841.00
+58.00(+7.41%)
Closed·

CRI1 Financial Summary

Key Ratios

P/E Ratio248.01
Price/Book15.88
Debt / Equity15.88%
Return on Equity10.3%
Dividend Yield26.16%
EBITDA35.50M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
2025
31/12
* In Millions of PLN (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -
Dividend Yield
26.16%
Industry Median -
Annualized payout
220.00
Paid unevenly
5-Years Growth
-
Growth Streak

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 919.00
(+9.27% Upside)

Earnings

Latest Release
Sep 02, 2026
EPS / Forecast
-- / --
Revenue / Forecast
52.25M / 52.5M
EPS Revisions
Last 90 days

FAQ

What was Creotech Instruments's net income for the latest quarter?

Creotech Instruments's net income for the latest quarter was 692.14.

How did Creotech Instruments's performance compare year-over-year in the latest quarter?

The company's revenue moved from 17.96 million PLN in the previous quarter to 68.64 million PLN in the latest quarter, and net income moved from -6.87 million PLN to 692.14 million PLN compared to the previous quarter.

What is Creotech Instruments's net profit margin on a TTM basis?

Creotech Instruments's trailing twelve months (TTM) net profit margin is 418.79%.

How does Creotech Instruments's debt to equity ratio compare to industry standards?

Creotech Instruments's total debt-to-equity ratio is 15.88%.

What is Creotech Instruments's return on investment on a TTM basis?

Creotech Instruments's trailing twelve months (TTM) return on investment (ROI) is 10.30%.

How has Creotech Instruments's total revenue grown this year?

Creotech Instruments's total revenue was 17.96 million PLN in the previous quarter and 68.64 million PLN in the latest quarter.

What is Creotech Instruments's gross margin on a TTM basis?

Creotech Instruments's trailing twelve months (TTM) gross margin is 95.09%%.

What was Creotech Instruments's revenue per share for the latest quarter?

Creotech Instruments's revenue per share for the latest quarter was 64.62.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.